DPM Secures Nearly RMB 100 Million in Series B+ Financing Led by Gree Capital and Haoshuo Investment, with WinX Capital as Exclusive Financial Advisor

VCBeat has learned that recently,DPM Company(including Beijing Digital Precision Medical Technology Co., Ltd. and Zhuhai Dipu Medical Technology Co., Ltd., hereinafter referred to as “DPM”)Announces Completion of Nearly 100 Million Yuan in Series B+ Financing, this round of financing was participated in by Gree Financial Investment under the Gree Group and Haoshuo Investment, with WinX Capital continuing to serve as the exclusive financial advisor.The proceeds from this round of financing will further accelerate the company's product innovation, market promotion, and team building.In July 2022, DPM completed a Series B financing round worth hundreds of millions of RMB, co-led by SoftBank China Capital and Zhongguancun Longmen Investment. Just over a month later, top-tier investment institutions made additional investments, fully demonstrating the capital market’s high recognition of DPM.

Precision medicine is a crucial pathway for enhancing diagnostic and therapeutic standards and achieving personalized healthcare. Molecular imaging technology has been recognized as one of the top ten most promising frontiers in medical science, with its emergence creating new opportunities for the advancement of precision medicine. The precision and intelligence of surgical procedures represent core areas where the medical field continues to break through technical barriers, and molecular imaging technology provides solutions in this domain. As a pioneer and leader in China’s molecular imaging sector, DPM possesses robust capabilities in technological innovation and product commercialization. Recently, DPM’s “Broad-Spectrum Super-Resolution Intelligent Endoscopic Molecular Imaging System” was successfully selected as a leading entity in the “Intelligent Adjunctive Therapy Products” category under the Ministry of Industry and Information Technology’s “Artificial Intelligence Medical Device Innovation Task.” DPM was also the only fluorescent endoscopy company chosen among all candidates in this review process. On August 26, DPM’s independently developed “Fluorescent Molecular Imaging Surgical Navigation System” won the Second Prize in the finals of the HICOOL 2022 National Entrepreneurship Competition. DPM will continue to deepen its expertise in the field of molecular imaging, contributing to the progress of precision medicine.

Professor Tian Jie, Chairman of DPMIt stated: “We extend our sincere gratitude to Gree Financial Investment, a subsidiary of Gree Group, and Haoshuo Investment for their recognition and expectations as investors in this round, as well as to SoftBank China Capital, Zhongguancun Longmen Investment, Hangzhou Risheng, and Jiangsu Haoyue Fund for their prior support and collaboration as Series B investors. DPM has consistently maintained close collaborations with leading medical experts both domestically and internationally, accumulating decades of R&D experience in the integration of medicine and engineering, and achieving systematic outcomes and technological breakthroughs in key areas. DPM will continue to deepen its focus on the field of molecular imaging, delivering more high-quality, innovative solutions for clinical practice, and contributing to the advancement of China’s healthcare industry.”

Li Ling, relevant person in charge of Gree Financial InvestmentStatement: As one of the revolutionary technologies in minimally invasive surgical equipment, fluorescence endoscopy has become a key competitive frontier for global endoscopy companies. Leveraging the Key Laboratory of Molecular Imaging of the Chinese Academy of Sciences, DPM possesses robust fundamental research capabilities in underlying technologies such as molecular imaging and artificial intelligence. By aligning with clinical needs, DPM has developed a series of high-end fluorescence molecular imaging surgical navigation systems. Against the backdrop of the localization of medical equipment manufacturing in China, DPM and its team are leading the rapid development of domestically produced fluorescence imaging devices through superior product performance and service systems. Zhuhai Gree Financial Investment Management Co., Ltd. will effectively fulfill its role as a state-owned capital investment and operation platform, further strengthening its support and cultivation of DPM to propel the ascent of China’s domestic healthcare industry.

Zhao Xiaobo, Partner at Haoshuo InvestmentStatement: It is a great honor to meet Professor Tian Jie and Dr. Chi Chongwei, along with their team of scientists at DPM, and to become part of the same family. As a sub-fund of the National Ministry of Science and Technology’s Achievement Transformation Fund, the Zhi’er Fund managed by Haoshuo Investment has been actively seeking and investing in outstanding startups like DPM that are commercializing scientific research achievements across various fields. DPM has participated in multiple major national scientific research programs, including the National 973 Program, Major Projects of the National Natural Science Foundation, and the Ministry of Science and Technology’s Nanotechnology Special Project. The translation of these specialized achievements into technologies and products in the field of precision medicine holds significant value for China’s life and health sector. We hope that Haoshuo Investment can grow alongside DPM and create a shared future!

Dr. Zou Guowen, Founding Partner of WinX CapitalIt was stated that fluorescence molecular imaging technology is an essential tool for future surgical procedures. Centered around Professor Tian and Dr. Chi, DPM has remained committed to product quality and guided by clinical needs in building its fluorescence molecular imaging technology platform. Since its market launch, the product has rapidly gained favor in clinical settings, driving a swift increase in the company’s revenue. After serving as the exclusive financial advisor to DPM and successfully assisting in closing its Series B financing, WinX Capital again acted as the exclusive financial advisor for the Series B+ round. Despite the current downturn in the primary market, the transaction was successfully closed, fully demonstrating the primary market’s confidence in DPM’s future development. We extend our gratitude to Zhuhai Gree Financial Investment Management Co., Ltd. and Shanghai Haoshuo Private Equity Fund Management Co., Ltd. for their strong support of DPM, as well as to DPM’s management team and existing shareholders for their trust in WinX Capital.

Supporting the real economy in scaling up, optimizing quality, and strengthening competitiveness, while empowering portfolio companies to achieve high-quality development

Gree Financial Investment is committed to building a first-class state-owned industrial investment institution that is “professional, market-oriented, distinctive, and branded.”

Zhuhai Gree Financial Investment Management Co., Ltd. (hereinafter referred to as “Gree Financial Investment”) was established in May 2017 with a registered capital of RMB 13 billion. As a wholly-owned subsidiary of Gree Group, Zhuhai’s first state-owned capital investment and operation platform, the company serves as a key industrial investment entity. Committed to becoming a driver for the introduction and upgrading of industries in Zhuhai, a new engine for accelerating the construction of a modern industrial system, and a top-tier innovative state-owned industrial investment institution characterized by “specialization, market orientation, distinctiveness, and branding,” the company was honored as one of the “Top 30 State-Owned Limited Partners in China’s Equity Investment Market 2022.”

Leaders and Drivers of the New Wave of National Innovation and Development

Dedicated to assisting high-tech innovation enterprises in securing resource support through industry cultivation.

Ningbo Zhi’er Venture Capital Partnership (Limited Partnership) (hereinafter referred to as the “Zhi’er Fund”) is a sub-fund of the National Science and Technology Achievement Transformation Fund. It is a private equity investment fund focusing on start-up, growth-stage, and mature enterprises in high-tech sectors such as pharmaceuticals and healthcare, TMT, and advanced manufacturing. Haoshuo Investment, serving as the manager of the Zhi’er Fund, is committed to assisting high-tech innovative enterprises in securing resource support through industry incubation. It aims to achieve investment returns while facilitating enterprise growth, thereby enhancing the efficiency of the national innovation system and positioning itself as a leader and driver in the new round of national innovation development. Its founders and core management team possess nearly 20 years of professional experience in industrial investment, capital operations, asset management, and securities market regulation, hailing from major domestic and international investment institutions, securities companies, securities regulatory authorities, and large state-owned enterprises.

Accumulating Small Wins into Major Victories, From Win to WinX

WinX Capital is a leading investment bank in China’s healthcare sector.

WinX Capital is a leading investment bank in China’s healthcare sector. Headquartered in Beijing and Shanghai, it serves over 3,000 active institutional investors and industrial groups. From 2020 to 2022, WinX Capital was consecutively recognized by Qimingpian & Xinsheng Chuangfu as “Top 2 Best Financial Advisors in Healthcare (2021–2022),” “Top 4 Best Financial Advisory Firms in Healthcare (2020),” “Top 10 Best Financial Advisors – Active List (2021),” “Top 6 Best Financial Advisors – Comprehensive List (Mid-2022),” and “Top 7 Best Financial Advisors – Active List (Mid-2022).” It was also ranked among the “Top 5 Most Promising Emerging Investment Banks in China (WISE 2020/2021)” by 36Kr, and named “Top 5 Healthcare Financial Advisor of the Year” at VCBeat’s 2022 Pengcheng Awards.